Milgamma N (Benfotiamine, Cyanocobalamin, Pyridoxine Hydrochloride)

Benfotiamine is a lipid‑soluble form of thiamine that readily enters cells and boosts transketolase activity. This reduces the accumulation of harmful metabolic by‑products such as advanced glycation end‑products, thereby protecting nerves from oxidative stress and supporting normal glucose metabolism.

The dosage of Milgamma N is individualized by the prescribing healthcare professional based on the patient’s condition, age, renal function and other factors. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

Limited clinical data are available on the use of Milgamma N in pregnancy or lactation. Because the safety of high‑dose B‑vitamins has not been fully established, it should only be used if the potential benefit justifies any possible risk, and under close medical supervision.

To order Milgamma N, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Milgamma N combines benfotiamine, cyanocobalamin and pyridoxine in a single tablet, offering targeted nerve‑protective actions that many standard B‑complex products lack. While generic B‑complexes provide a broad vitamin profile, Milgamma N’s specific formulation is intended for neuropathic conditions and has documented metabolic benefits beyond basic supplementation.

Milgamma N tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Milgamma N is taken orally, usually with water. The tablet should be swallowed whole and can be taken with or without food, unless the prescriber advises otherwise. Patients should adhere to the dosing schedule provided by their healthcare professional.

Serious adverse reactions, although rare, include severe allergic responses such as anaphylaxis, Stevens‑Johnson skin syndrome, hemolytic anemia in individuals with G6PD deficiency, and significant liver enzyme elevations. Any signs of rash, swelling, breathing difficulty, or jaundice require immediate medical attention.

Milgamma N should be avoided in individuals with known hypersensitivity to any of its ingredients, those with severe renal impairment without dose adjustment, patients with G6PD deficiency at risk of hemolysis, and anyone for whom a prescriber determines that the risks outweigh the benefits.